Synapse - Department of Medicine

Results (39619)

Treatment patterns and outcomes following progression of disease post-CAR-T therapy in relapsed or refractory mantle cell lymphoma: A multicenter analysis

Meeting Abstract

Epstein-Peterson, Z. D.; Lionel, A. C.; Joseph, A.; Drill, E.; Atallah-Yunes, S. A.; Brooks, T. R.; Chong, E. A.; Chong, E. R.; Dela Cruz, J.; Frank, M. J.; more...
Blood (2024)

Fulltext@MSK | Save

TP53 alterations confer increased risk of leukemic transformation and worse survival as compared to high molecular risk mutations in patients with myeloproliferative neoplasms

Meeting Abstract

Handa, S.; Riazat-Kesh, Y. J. R. A.; Butterfield, R. J.; Sivakumar, G.; Venugopal, S.; McGovern, E.; Feld, J.; Tremblay, D.; Elghaity-Beckley, S.; Kremyanskaya, M.; more...
Blood (2024)

Fulltext@MSK | Save

The effect of biosimilar entry on biologic drug prices in Medicare part B

Meeting Abstract

Winn, A.; Abdelaziz, A.; Dusetzina, S. B.; Mitchell, A. P.
Value in Health (2024)

Fulltext@MSK | Save

Matching-adjusted indirect comparison (MAIC) of safety outcomes with MET tyrosine kinase inhibitors (TKIs) in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)

Meeting Abstract

Taylor, K.; Veillon, R.; Griesinger, F.; Reinmuth, N.; Ghori, V.; Vioix, H.; Clark, A.; Paik, P.
Value in Health (2024)

Fulltext@MSK | Save

Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R/R) KMT2Ar acute leukemia

Meeting Abstract

Aldoss, I.; Issa, G. C.; Blachly, J. S.; Thirman, M. J.; Mannis, G. N.; Arellano, M. L.; DiPersio, J. F.; Traer, E.; Zwaan, C. M.; Shukla, N.; more...
Blood (2024)

Fulltext@MSK | Save

Gilteritinib results in higher remission and transplant rates than midostaurin but does not increase the post-induction mutational MRD negative rate: Results of the phase 2 randomized PrECOG 0905 study in newly diagnosed FLT3 mutated AML